ArticleBMC infectious diseases2026
Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explanatory Modeling of Tuberculosis Treatment Outcomes: The Role of Community Engagement and Clinical Governance.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe treatment of drug-resistant tuberculosis (DR-TB) is complex, longer, and it is associated with adverse drug reactions, contributing to higher morbidity and mortality rates. DR-TB presents a serious public health challenge, particularly in low- and middle-income countries where the burden is highest. We assessed DR-TB success rates and associated factors in Tanzania.
methodsWe collected data from DR-TB national data base and analyzed final treatment outcomes of 1,998 DR-TB patients registered for the six years (2017–2022) contributing 69% of the total DR-TB patients started on treatment in Tanzania since 2009. Factors associated with treatment outcomes were determined through multivariable analysis using logistic regression.
resultsThe overall treatment success rate for DR-TB was 80% (n = 1,594). Factors influencing treatment success included age, nutritional status, HIV serostatus, and specific treatment regimens. Patients aged 15–29 years had a significantly higher likelihood of treatment success (aOR: 1.83, 95% CI: 1.26–2.64). Normal nutritional status at baseline was associated with higher treatment success (aOR: 4.14, 95% CI: 3.01–5.68), as was HIV-negative status (aOR: 1.51, 95% CI: 1.16–1.95). Specific regimens such as Standard Short Regimen (S-SCR) and All Oral Modified Shorter Regimen (AOSR) were significantly associated with higher treatment success (aORs: 1.62, 95% CI: 1.12–2.36 and 2.37, 95% CI: 1.43–3.90, respectively).
conclusionThe study highlights that younger age groups, normal nutritional status, HIV-negative status, and specific treatment regimens like S-SCR and AOSR are significant influencing factors of DR-TB treatment success. To improve DR-TB treatment success rates the national TB program in Tanzania could prioritize the use of S-SCR and AOSR regimens, ensure a good nutritional status at baseline and appropriate management of HIV co infected DR-TB patients. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.